Physiology-Based Targeted Therapy: Development of the first Pharmacotherapy for Sleep Apnoea
Flinders University and Mobius Medical are collaborating on a groundbreaking initiative to develop a new drug therapy for sleep apnoea. This project aims to generate foundational knowledge to support pivotal multi-centre clinical trials and expand treatment options for those with obstructive sleep apnoea.
Industry Insights:
Mobius Medical is delighted to be partnering with Flinders University on this project, with Technical Director Richard Brookes commenting, “At Mobius, our partnership in the National Industry PhD program exemplifies our commitment to pioneering research and fostering industry-academic collaboration for real-world challenges.
University Contributions:
Professor Danny Eckert, Director of Sleep Health at Flinders University, highlights the project’s importance: “There are no approved medications to treat obstructive sleep apnoea, affecting over 1 million Australian adults, where current device-based therapies are often inadequate.”
Student Perspective:
PhD student Emma Thomas states, “This collaboration brings precision medicine techniques together with Mobius Medical to develop the first drug for sleep apnoea, potentially helping millions globally.”
Anticipated Outcomes:
Data from this project will be crucial in commercialising and making the first targeted therapy for sleep apnoea publicly accessible. Combining technologies from Flinders University and Mobius Medical aims to provide a safe, effective medication for the 1 billion people globally affected by sleep apnoea, positively impacting the wider Australian community.
Thank you to Nilla Wen at Flinders University for her support and facilitation.